Simulations Plus, Inc. (NASDAQ:SLP) Given Average Rating of "Buy" by Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) have been given a consensus rating of "Buy" by the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $49.40.

A number of research analysts have issued reports on the company. BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. StockNews.com lowered shares of Simulations Plus from a "hold" rating to a "sell" rating in a research report on Monday, November 4th. Stephens initiated coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an "overweight" rating and a $39.00 price objective on the stock. William Blair reissued an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Finally, KeyCorp lifted their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, January 24th.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares of the company's stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 19.40% of the company's stock.

Institutional Investors Weigh In On Simulations Plus

Hedge funds have recently made changes to their positions in the company. Olympiad Research LP purchased a new position in Simulations Plus during the 4th quarter valued at about $211,000. Rice Hall James & Associates LLC lifted its holdings in shares of Simulations Plus by 19.4% during the fourth quarter. Rice Hall James & Associates LLC now owns 91,500 shares of the technology company's stock valued at $2,552,000 after purchasing an additional 14,871 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Simulations Plus by 4.5% during the fourth quarter. Principal Financial Group Inc. now owns 91,177 shares of the technology company's stock valued at $2,543,000 after purchasing an additional 3,904 shares during the last quarter. Stephens Inc. AR purchased a new stake in shares of Simulations Plus in the 4th quarter worth approximately $905,000. Finally, Conestoga Capital Advisors LLC grew its stake in shares of Simulations Plus by 15.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company's stock worth $62,090,000 after buying an additional 290,414 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.

Simulations Plus Stock Up 4.0 %

NASDAQ SLP traded up $1.35 on Friday, reaching $35.50. The company had a trading volume of 231,171 shares, compared to its average volume of 306,953. The stock has a market capitalization of $713.20 million, a P/E ratio of 88.75 and a beta of 0.82. The company's fifty day moving average is $30.56 and its 200 day moving average is $32.42. Simulations Plus has a 52-week low of $24.00 and a 52-week high of $51.22.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.